Enanta Pharmaceuticals (ENTA) Long-Term Investments (2012 - 2026)

Enanta Pharmaceuticals has reported Long-Term Investments for 15 years, with the latest figure at $63.2 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $63.2 million; the trailing twelve-month figure through Mar 2026 stood at $63.2 million (changed N/A YoY), and the FY2022 full-year result was $29.3 million, down 72.99% from the prior year.
• Long-Term Investments for Q1 2026 stood at $63.2 million, up from $56.1 million in the prior quarter.
• The five-year high for Long-Term Investments was $63.2 million in Q1 2026, with the low at $5.9 million in Q2 2023.
• Historically, Long-Term Investments has averaged $35.6 million across 5 years, with a median of $39.4 million in 2022.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 84.97% — and 2024, when it surged 617.59%.
• Enanta Pharmaceuticals' Long-Term Investments stood at $26.9 million in 2022, then sank by 78.01% to $5.9 million in 2023, then surged by 617.59% to $42.5 million in 2024, then jumped by 31.86% to $56.1 million in 2025, then increased by 12.81% to $63.2 million in 2026.
• The last three Long-Term Investments figures came in at $63.2 million (Q1 2026), $56.1 million (Q4 2025), and $42.5 million (Q2 2024), per Business Quant data.